TNFSF10 and prostate cancer: CTSE promotes tumor cell apoptosis by releasing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and enhances chemosensitivity to doxorubicin in prostate cancer models [34,35,36].